Since inhibition of NLRP3 in iMGL from healthy controls impacted NLRP3 and in part NLRC4 inflammasome pathway activation, we questioned the impact of NLRP3 inhibition in iMGL generated from ALS patients harboring SOD1 pathogenic mutations. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.